Hemostemix at Invest Stuttgart

Rhea-AI Summary

Hemostemix Inc. (HMTXF) will participate in Invest Stuttgart 2025, Germany's leading finance and investment conference, from May 9-10, 2025. The company specializes in autologous stem cell therapies, with its flagship product ACP-01 treating various cardiovascular conditions. The therapy has demonstrated safety and efficacy across 498 patients and seven clinical studies.

The company has introduced ACP-01 Therapy Convertible Debentures (TCDs) as an innovative financing instrument, offering 6% annual interest payable in shares. TCDs can be converted into either ACP-01 therapy or common shares. Hemostemix has already sold over CAD $1.14 million of TCDs, supporting revenue forecasting and treatment scheduling.

Calgary, Alberta--(Newsfile Corp. - May 8, 2025) -  Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VF0) ("Hemostemix" or the "Company") is poised to make a significant impact at Invest Stuttgart 2025, Germany's premier finance and investment conference, taking place from May 9-10, 2025 at Messe Stuttgart. The event attracts thousands of investors, financial professionals, and innovators, offering a dynamic platform for Hemostemix to showcase its advancements and connect with potential ACP-01 clients and new shareholders.

Hemostemix: A Leader in Autologous Stem Cell Therapy

Hemostemix stands at the forefront of regenerative medicine, specializing in autologous stem cell therapies. The flagship product, ACP-01, utilizes angiogenic cell precursors derived from a patient's own blood to treat a range of cardiovascular and conditions, including no-option:

• Peripheral Arterial Disease (PAD)

• Chronic Limb-Threatening Ischemia (CLTI)

• Ischemic Cardiomyopathy

• Non-Ischemic Dilated Cardiomyopathy

• Congestive Heart Failure

• Angina

• Vascular Dementia (Phase I)

With over 498 patients treated and seven clinical studies completed, Hemostemix has demonstrated the safety, clinical relevancy and statistical efficacy across multiple indications.

Innovative Financing: ACP-01 Therapy Convertible Debentures

To support its growth and commercialization efforts, Hemostemix has introduced ACP-01 Therapy Convertible Debentures (TCDs). These instruments provide non-dilutive capital, largely, allowing the company to scale production and expand its clinical reach. Key features include:

• Conversion Options: Each TCD can be converted into an ACP-01 therapy or into Hemostemix Common Shares.

• Interest: 6% per annum, payable in shares.

• Transferability: TCDs are transferable, will-able, sale-able.

• As of early 2025, Hemostemix has sold over CAD $1.14 million of TCDs, facilitating

  • Forecast of revenue.

  • Scheduling of production.

  • Scheduling of treatments.

This approach supports operational scalability but also aligns production and treatments with patient demand, fostering sustainable growth.

Conclusion

Hemostemix's participation in Invest Stuttgart 2025 underscores its commitment to advancing regenerative medicine, selling ACP-01 globally to no-option patients, and delivering shareholder value. By leveraging its pioneering therapies and innovative financing strategies, the company is well-positioned to transform the treatment landscape for vascular and cardiac diseases.

ABOUT HEMOSTEMIX

Hemostemix is an autologous stem cell therapy platform company, founded in 2003. A winner of the World Economic Forum Technology Pioneer Award, the Company has developed, patented, is scaling and selling ACP-01, an autologous (patient's own) blood-based stem cell therapy. Hemostemix has completed seven clinical studies of 318 subjects and published its results in nine peer reviewed publications. ACP-01 is safe, clinically relevant and statistically significant as a treatment for peripheral arterial disease, chronic limb threatening ischemia, non ischemic dilated cardiomyopathy, ischemic cardiomyopathy, congestive heart failure, and angina. Hemostemix completed its Phase II clinical trial for chronic limb threatening ischemia and published its results in the Journal of Biomedical Research & Environmental Science, including a significant reduction in ulcer size: 1.48 cm^2 to 0.48 mm^2 within 3 months (p=0.01) while placebo did not exhibit a change (p<0.54). At 1 year, treated vs placebo amputation (4.8% vs 25%), and mortality (4.8% vs 12.5%), was noted. As compared to a five year mortality rate of 60% in the CLTI patient population, UBC and U of T reported to the 41st meeting of vascular surgeons: 0% mortality, cessation of pain, wound healing in 83% of patients followed for up to 4.5 years, as a midpoint result.

For further information, please contact: Thomas Smeenk, President, CEO & Co-Founder

EM: tsmeenk@hemostemix.com PH: 905-580-4170

Neither the TSX Venture Exchange nor its Regulation Service Provider (as that term is defined under the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release. Forward-Looking Information: This news release contains "forward-looking information" within the meaning of applicable Canadian securities legislation. All statements, other than statements of historical fact, included herein are forward-looking information. In particular, this news release contains forward-looking information in relation to: the sales of ACP-01 as an exempt compassionate treatment, the licensing of ACP-01, the Trademark Know Your Health! and related results, including the commercialization of ACP-01. ‎‎There can be no assurance that such forward-looking information will prove to be accurate. Actual results and future events could differ materially from those anticipated in such forward-looking information. This forward-looking information reflects Hemostemix's current beliefs and is based on information currently available to Hemostemix and on assumptions Hemostemix believes are reasonable. These assumptions include, but are not limited to: the underlying value of Hemostemix and its Common Shares; the successful resolution of the litigation that Hemostemix is pursuing or defending (the "Litigation"); the results of ACP-01 research, trials, studies and analyses, including the analysis being equivalent to or better than previous research, trials or studies; the receipt of all required regulatory ‎approvals for research, trials or studies; the level of activity, market acceptance and market trends in the healthcare sector; the ‎economy generally; consumer ‎interest in Hemostemix's services and products; competition and ‎Hemostemix's competitive advantages; and Hemostemix obtaining satisfactory financing to ‎ fund Hemostemix's operations including any research, trials or studies, and any Litigation. Forward-looking information is Subject to known and unknown risks, uncertainties and other factors that may cause the actual results, level of activity, performance or achievements of Hemostemix to be materially different from those expressed or implied by such forward-looking information. Such risks and other factors may include, but are not limited to: the ability of Hemostemix to complete clinical trials, complete a satisfactory analyses and file the results of such analyses to gain regulatory approval of a phase II or phase III clinical trial of ACP-01; potential litigation Hemostemis mayface; general business, economic, competitive, political and social uncertainties; general capital market conditions and market prices for securities; delay or failure to receive board or regulatory approvals; the actual results of future operations including the actual results of future research, trials or studies; competition; changes in legislation ‎affecting Hemostemix; the timing and availability of external financing on acceptable terms; long-term capital requirements and future developments in Hemostemix's markets and the markets in which it expects to compete;‎ lack of qualified, skilled labour or loss of key individuals; and risks ‎related to the COVID-19 pandemic including various recommendations, orders and measures of governmental authorities to ‎try to limit the pandemic, including travel restrictions, border closures, non-essential business closures service disruptions, quarantines, self-isolations, shelters-in-place and social distancing, disruptions to markets, disruptions to economic activity and ‎financings, disruptions to supply chains and sales channels, and a deterioration of general economic conditions including a ‎possible national or global recession or depression;the potential impact that the COVID-19 pandemic may have on Hemostemix which may include a decreased demand for the services that Hemostemix offers; and a deterioration of financial markets that could limit Hemostemix's ability to obtain external financing. A description of additional risk factors that may cause actual results to differ materially from forward-looking information can be found in Hemostemix's disclosure documents on the SEDAR website at www.sedarplus.ca. Although Hemostemix has attempted to identify important factors that could cause actual results to differ materially from those contained in forward-looking information, there may be other factors that cause results not to be as anticipated, estimated or intended. Readers are cautioned that the foregoing list of factors is not exhaustive. Readers are further cautioned not to place undue reliance on forward-looking information as there can be no assurance that the plans, intentions or expectations upon which they are placed will occur. Forward-looking information contained in this news release is expressly qualified by this cautionary statement. The forward-looking information contained in this news release represents the expectations of Hemostemix as of the date of this news release and, accordingly, it is Subject to change after such date. However, Hemostemix expressly disclaims any intention or obligation to update or revise any forward-looking information, whether as a result of new information, future events or otherwise, except as expressly required by applicable securities law.

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/251294

FAQ

What will Hemostemix (HMTXF) present at Invest Stuttgart 2025?

Hemostemix will showcase its ACP-01 autologous stem cell therapy and innovative financing through ACP-01 Therapy Convertible Debentures (TCDs) at the conference.

What are the key features of Hemostemix's ACP-01 Therapy Convertible Debentures (TCDs)?

TCDs offer 6% annual interest payable in shares, can be converted into ACP-01 therapy or common shares, and are transferable. The company has sold over CAD $1.14 million in TCDs.

How many patients has Hemostemix's ACP-01 therapy treated?

Hemostemix has treated 498 patients through seven clinical studies, demonstrating safety and efficacy across multiple cardiovascular conditions.

What medical conditions does Hemostemix's ACP-01 therapy treat?

ACP-01 treats conditions including Peripheral Arterial Disease, Chronic Limb-Threatening Ischemia, Ischemic Cardiomyopathy, Non-Ischemic Dilated Cardiomyopathy, Congestive Heart Failure, Angina, and Vascular Dementia (Phase I).